Company* (Symbol)




Status (Date)


Aphton Corp. (APHT)


Anti-gastrin therapeutic vaccine; neutralizes hormone G17 and Gly-extended G17

Metastatic gastric cancer

Initiated pivotal trial (4/28)

Antigenics Inc. (AGEN)


Cancer vaccine consisting of purified, patient-specific heat shock protein-peptide complexes


Presented Phase I/II data at the 91st annual meeting of the American Association for Cancer Research in San Francisco (AACR) (4/5)

Avax Technologies Inc. (AVXT)


Therapeutic vaccine; tumor cells removed from patient, modified with hapten (DNP; dinitrophenyl), then injected back into patient (along with cyclophosphamide)

Metastatic melanoma

Presented T cell response data at AACR (5/4)

BioTransplant Inc. (BTRN)

AlloMune Cancer System

Mixed chimerism approach whereby patients are prepared for a bone-marrow or stem-cell transplant with a combination of low-dose chemotherapy and antibodies against T cells

Refractory Hodgkin's and non-Hodgkin's lymphoma

Initiated Phase I/II trial (4/6)

Coley Pharmaceutical Group Inc.*

CpG 7909

DNA-based immune stimulant

Relapsed or refractory non-Hodgkin's lymphoma

Initiated Phase I/II trial (4/17)

CollaGenex Pharmaceuticals Inc. (CGPI)


Orally administered inhibitor of matrix metalloproteinases

HIV-associated Kaposi's sarcoma

Released initial findings from Phase I trial (4/4)

Coulter Pharmaceutical (CLTR) and SmithKline Beecham plc (NYSE:SBH)


Tositumomab iodine I-131; radioimmunotherapy involving an antibody conjugated to iodine-131 that attaches to a protein found on the surface of B cells

Previously untreated low-grade non-Hodgkin's lymphoma

Initiated Phase II trial of combination therapy using cyclophosphamide, vincristine and prednisone (4/26)

EntreMed Inc. (ENMD)


Recombinant human anti-angiogenic protein


Initiated Phase I trial (4/11)

Genta Inc. (GNTA)

Genasense (G3139)

Antisense compound; synthetic DNA strands that bind to mRNA for the bcl2 gene (proto-oncogene)

Advanced malignant melanoma

Updated results of Phase I/IIa trial at AACR (4/4)

Hoffmann-La Roche Inc. (U.S. prescrip-drug unit of the Roche Group; Switzerland)


Capecitabine; oral anticancer agent

Metastatic colorectal cancer

Phase II trial results published in the 4/00 issue of the Journal of Clinical Oncology (4/19)

MGI Pharma Inc. (MOGN)

Irofulven (MGI 114)

Hydroxymethylacyfulvene; lead compound from acylfulvene family

Ovarian cancer

Presented interim Phase II trial data at AACR (4/6)


Combreta-statin A4 Prodrug (CA4P)

Angiogenesis inhibitor

Advanced cancer

Presented preliminary Phase I trial results at AACR (4/5)

Novelos Therapeutics Inc.*


Formulation that stabilizes a natural human peptide in its oxidized form; peptide has antitumor and chemoprotective effects, and stimulates hematopoiesis and the immune system

Late-stage non-small-cell lung cancer

Initiated Phase I/II trial (4/19)

SafeScience Inc. (SAFS)


Carbohydrate lectin inhibitor that competitively binds to unique lectins on cancer cells and disrupts the metastatic process

Pancreatic carcinoma

Initiated dosing in Phase II trial at Beth Israel Deaconess Medical Center (4/11) and the University of Chicago Medical Center (4/19)

SciClone Pharmaceuticals (SCLN)


Thymosin alpha 1; synthetic version of naturally occurring peptide hormone thymosin (immunomodulator)

Metastatic malignant melanoma

Data from open-label Phase II trial of Zadaxin combined with chemotherapy published in 4/00 issue of Melanoma Research (4/6)


Alteon Inc. (OTC BB: ALTN)


AGE cross-link breaker; orally active compound that breaks cross-linked advanced glycosylation end products

Cardiovascular disease due to aging or diabetes

Initiated Phase IIa trial (4/6)

CytRx Corp. (CYTR)


Purified poloxamer 188; surfactant molecule that alters the way cells and molecules interact with water

Sickle cell disease

Presented data from four studies at the 24th annual meeting of the National Sickle Cell Disease Program in Philadelphia (4/17)

Discovery Therapeutics Inc.* and Fujisawa Healthcare Inc. (Japan)


Orally active molecule that acts at the A1 and A2 receptor subtypes

Cardiac arrhythmias characterized by chaotic or abnormally rapid heartbeats

Initiated Phase II trial (4/24)

GenVec Inc.*


Angiogenic gene therapy that delivers vascular endothelial growth factor 121

Coronary artery disease and peripheral vascular disease

Initiated Phase II trial (4/26)

Icos Corp. (ICOS)


Humanized monoclonal antibody that blocks CD11/CD18-mediated cell adhesion (inhibits movement of neutrophils from blood into tissue)

Ischemic stroke

Failed to achieve efficacy endpoint in interim analysis (4/20)

Neurobiological Technologies Inc. (OTC BB:NTII) and Merz + Co. GmbH & Co. (Germany)


Orally available neuroprotective agent that appears to restore damaged nerve cells and block excitatory signals by modulating the N-methyl D-aspartate (NMDA) receptor on cell membranes

Mild to moderate vascular dementia

Reported positive results in two Phase III trials at the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer's Therapy (4/10)

V.I. Technologies Inc. (VITX)

Universal PLAS+SD

Plasma transfusion product that inactivates lipid-enveloped viruses including HIV, hepatitis B and hepatitis C, and is depleted of antibodies that cause plasma to be blood-type specific


Initiated Phase III pivotal trial (4/4)


Boston Life Sciences Inc. (BLSI)


Radioimaging probe for dopamine neurons

Diagnosis of attention deficit hyperactivity disorder

Initiated Phase II trial (4/6); reported results of Phase II evaluation of scans by outside specialists (4/25)

Centaur Pharmaceuticals Inc.*


Small-molecule agent that modifies cellular response to stress

AIDS dementia complex

Completed enrollment in Phase II trial (4/25)

Diacrin Inc. (DCRN)


Porcine neural cells for transplantation in stroke patients


Phase I trial put on hold while company investigates the cause of two adverse events; the FDA is expected to work with investigators to evaluate the events; Diacrin will not restart the study without the FDA's concurrence (4/17)

Inhale Therapeutic Systems Inc. (INHL) and Biogen Inc. (BGEN)

Avonex (inhalable)

Powder formulation of Avonex (interferon beta-1a) for inhalation

Multiple sclerosis

Initiated dosing in Phase I trials (4/18)

MacroChem Corp. (MCHM)


Topical treatment combining ibuprofen and drug-absorption enhancement agent called SEPA (soft enhancement of percutaneous absorption)

Localized pain

Completed analysis of trial (4/7)

Nastech Pharmaceutical Co. (NSTK)


Intranasal formulation of morphine

Third-molar dental extraction

Reported data from pilot efficacy trial (4/4)

Nastech Pharmaceutical Co. (NSTK)


Intranasal formulation of apomorphine

Erectile dysfunction

Completed pilot studies (4/11)

NeoTherapeutics Inc. (NEOT)

Neotrofin (AIT-082)

Leteprinim potassium; small-molecule compound designed to cross blood-brain barrier and enhance nerve cell function by increasing levels of neurotrophic factor

Alzheimer's disease

Completed enrollment in Phase IIb trial (4/5); initiated open-label extension of trial (4/6)

Neurocrine Biosciences Inc. (NBIX)

NBI 5788

Altered peptide ligand targeting T cells that bind to myelin sheath

Relapsing remitting multiple sclerosis

Reported results of Phase II trial (4/4)

Neurocrine Biosciences Inc. (NBIX)


Interleukin-4 Pseudomonas toxin fusion protein; chimeric protein linking interleukin-4 (which binds to cancer cells because they express elevated levels of the IL-4 receptor) and Pseudomonas exotoxin (a cytotoxin)

Advanced malignant glioma

Reported results of Phase I/II trial (4/27)

Teva Pharmaceutical Industries (Israel;TEVA) and H. Lundbeck A/S (CSE:LUN.CO)


Selective irreversible MAO-B inhibitor

Parkinson's disease

Reported positive Phase III results (4/7)


DepoMed Inc. (AMEX:DMI)

Metformin GR

Extended-release dosage formulation of metformin


Presented results from Phase I trial at the Millennial World Congress of Pharmaceutical Sciences in San Francisco (4/18)


Enzon Inc. (ENZN) and Schering-Plough Corp. (NYSE:SGP)


Long-acting dosage form of Schering's Intron A (recombinant interferon alfa-2b) conjugated to polyethylene glycol

Hepatitis C

Reported positive results in Phase III trial comparing product to Intron A (interferon alfa-2b, recombinant; marketed by Schering-Plough); data to be presented at the European Association for the Study of the Liver annual meeting on 5/1 (4/18)

Gilead Sciences Inc. (GILD)


Tenofovir disopoxil fumarate; reverse transcriptase inhibitor

Treatment-experienced HIV infection

Reported preliminary results of Phase II trial (4/16); presented data at the International Conference for Antiviral Research in Baltimore (4/17)

Gilead Sciences Inc. (GILD)


Adefovir dipivoxil; reverse transcriptase inhibitor

Chronic hepatitis B infection resistant to lamivudine

Presented data from open-label trial at the 10th International Symposium on Viral Hepatitis and Liver Disease in Atlanta (4/11)

The Immune Response Corp. (IMNR) and Agouron Pharmaceuticals (subsidiary of Warner-Lambert Co. [NYSE:WLA])


Envelope-depleted, inactivated AIDS virus (emulsified with adjuvant)

HIV infection

Immune response data published in AIDS Research and Human Retroviruses (4/13)

Maxim Pharmaceuticals (MAXM)


Histamine dihydrochloride; H2 receptor agonist

Hepatitis C infection

Presented 24-week results from Phase II combination trial with interferon-alpha at the 10th International Symposium on Viral Hepatitis and Liver Disease in Atlanta (4/12)

Periodontix Inc.*


Silver ions delivered locally via a bioresorbable wafer


Presented results of Phase I trial at the International Association for Dental Research conference in Washington (4/10)

Synsorb Biotech Inc. (Canada; SYBB)

Synsorb Cd

Product that binds to toxins secreted by bacteria in the gastrointestinal tract

Prevention of recurrent Clostridium difficile antibiotic-associated infection

Initiated Phase III trials (4/3)

Triangle Pharmaceuticals Inc. (VIRS)


Emtricitabine; antiviral nucleoside analogue

HIV infection

South African Medicines Control Agency said Study FTC-302 should be terminated (4/6)

ViroPharma Inc. (VPHM)


Oral liquid formulation of a small-molecule inhibitor of several RNA viruses (blocks replication)

Viral respiratory infection in adults

Phase III did not achieve statistical significance in primary endpoint of time to resolution of illness (4/11)

ViroPharma Inc. (VPHM)


Oral liquid formulation of a small-molecule inhibitor of several RNA viruses (blocks replication)

Viral meningitis in adults and children

Reported data from two Phase III trials, one in adults and one in children; product did not achieve primary endpoint of reduction in time to complete resolution of headache (4/11)


Abgenix Inc. (ABGX)


Fully human monoclonal antibody that targets interleukin-8

Moderate to severe psoriasis

Initiated first Phase II trial (4/3)

Amarillo Biosciences Inc. (OTC BB: AMAR)


Oral interferon alpha

Primary Sjogren's syndrome

Completed first 24-week Phase III trial (4/7)

Corixa Corp. (CRXA) and NV Organon (The Netherlands)


A complex of solubilized HLA with a specific peptide from the human cartilage glycoprotein HCgp39

Rheumatoid arthritis

Completed Phase I/II trial (4/17)

Entropin Inc. (ETOP)

Esterom Solution

Topical liquid solution containing three cocaine derivatives ­ benzoylecgonin, ecgonine and ecgonidine

Range of motion difficulties due to shoulder dysfunction and back strain

Reported enrollment of almost 100 patients in Phase IIIa trial; enrollment expected to be complete by 6/00 (4/6)

Icos Corp. (ICOS)

Pafase (formerly rhPAF-AH)

Recombinant platelet-activating factor acetylhydrolase; degrades PAF and thereby lessening inflammatory response

Patients with severe sepsis or severe traumatic injuries at risk for development of acute respiratory distress syndrome

Reported data from Phase II trial (4/20)

Inflazyme Pharmaceuticals Ltd. (TSE:IZP) and Aventis Pharma (France; NYSE:AVE)


Oral compound based on a molecule originally isolated from a sea sponge; inflammation mediator


Announced results of Phase I trials and plans to initiate Phase IIa trials mid-year (4/6)

La Jolla Pharmaceutical Co. (LJPC)

LJP 394

Molecule (toleragen) that binds to surface of B cells and shuts off production of antibodies to double-stranded DNA


Presented methods and results of a blood test used in analyzing data from lupus trials at Keystone Symposia 2000 in Steamboat Springs, Colo. (4/4)

Ortec International Inc.

Composite Cultured Skin

Tissue-engineered dressing consisting of two layers of human-derived skin cells (dermal and epidermal) supported with a porous collagen matrix

Venous ulcers

Presented preliminary trial data at the 13th Annual Symposium on Advanced Wound Care and Medical Research Forum in Dallas (4/7)

PPL Therapeutics (UK; LSE:PTH)

Bile Salt Stimulated Lipase Product (BSSL)

Transgenically produced recombinant human protein

Pancreatic insufficiency

Reported Phase II results (4/4)

Unigene Laboratories Inc. (OTC BB: UGNE) and Warner-Lambert Co. (NYSE:WLA)


Oral formulation of calcitonin


Initiated Phase I/II trial (4/12)


* Privately held.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; SBI=Stockholm Borsinformation; SSE = Swedish Stock Exchange; TSE = Toronto Stock Exchange

ND = Not disclosed.

AACR = 91st annual meeting of the American Association for Cancer Research in San Francisco.